## TECH: Bio-Techne Corporation - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 8.0% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($61.40)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Maryland Representative April McClain Delaney Purchased as Much as $135,000 in Bio-Techne Shares**
- Source: Bitget | 20260106T150825 | Somewhat-Bullish | Relevance: 100%
- Maryland Representative April McClain Delaney recently purchased between $9,009 and $135,000 worth of Bio-Techne (NASDAQ: TECH) shares on December 2, 2025. This transaction is part of her extensive trading activity over the past three years, totaling over $371,000 across 147 stock trades. Congressional members are required to disclose such transactions under the STOCK Act, which aims to prevent the use of insider information for personal financial gain.

**2. Maryland Representative April McClain Delaney Purchased as Much as $135,000 in Bio-Techne Shares**
- Source: Bitget | 20260105T230912 | Somewhat-Bullish | Relevance: 100%
- Maryland Representative April McClain Delaney recently purchased between $9,009 and $135,000 worth of Bio-Techne (NASDAQ: TECH) shares on December 2, 2025. This transaction is part of her 147 stock trades over the past three years, totaling over $371,000, and highlights the ongoing requirement for transparency in congressional stock transactions under the STOCK Act. Monitoring such trades can offer insights for investors, though they should not be the sole basis for investment decisions.

**3. Bio-Techne Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20260105T163000 | Bullish | Relevance: 100%
- Bio-Techne Corp. (TECH) saw its stock price rally by 5.67% to $63.03 on Monday, outperforming the broader market. This positive performance occurred during an overall favorable trading session, where the S&P 500 Index and Dow Jones Industrial Average also rose. This marks the second consecutive day of gains for Bio-Techne Corp.'s stock.

**4. Should Bio-Techne’s (TECH) Revenue Miss Raise Doubts About Its Scientific Platform’s Commercial Potential?**
- Source: Simply Wall Street | 20260104T225021 | Somewhat-Bearish | Relevance: 100%
- Bio-Techne recently reported softer third-quarter results with revenue 1.7% below analyst expectations, raising questions about its ability to convert its scientific platform into consistent commercial growth. Despite this, the company's expanding spatial biology collaborations offer a promising long-term growth outlook in precision medicine. Bio-Techne's narrative projects significant revenue and earnings growth by 2028, with a fair value estimate suggesting a 16% upside from its current price.

**5. Bio-Techne Corp (NASDAQ:TECH) Given Consensus Rating of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20260104T084327 | Somewhat-Bullish | Relevance: 100%
- Bio-Techne Corp (NASDAQ:TECH) has received a consensus "Moderate Buy" rating from eighteen analysts, with an average 12-month price target of $71.00. The company's stock opened at $59.65, has a market cap of $9.29 billion, and a P/E ratio of 121.7. Bio-Techne recently reported quarterly EPS of $0.42, meeting estimates, while revenue of $286.6 million missed forecasts and was down approximately 1% year-over-year.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Evercore ISI Gr | $62 | $68 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Evercore ISI Gr | down | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +7.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 30.2x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.2B |
| Beta | 1.47 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 30.2 |
| Current P/E | 33.1 |
| YoY Growth | 9.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.7% to 8.0% (+7.4% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (8.0% > 6.0%), caution on chasing. MRS_5 at 5.9% confirms short-term momentum alignment. Outperforming sector by 6.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.64), confirming momentum. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 8.04% (CS: 93) | Strong |
| RSI_14 | 69.3 | Neutral |
| MACD Histogram | 0.64 | Bullish |
| vs SMA20 | 1.098x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 1.183x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $65.28
- **Stop Loss:** $61.40 (5.9% risk)
- **Target:** $69.16 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 340
- **Position Value:** $22,195.20
- **Portfolio %:** 22.20%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*